Impact of high-fat diet on liver genes expression profiles in mice model of nonalcoholic fatty liver disease

Badman, 2007, Hepatic fibroblastgrowth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states, Cell Metab., 5, 426, 10.1016/j.cmet.2007.05.002 Balasubramanian, 2013, Asparagine synthetase: regulation by cell stress and involvement in tumor biology, Am. J. Physiol. Endocrinol. Metab., 304, 789, 10.1152/ajpendo.00015.2013 Bardowell, 2012, Disruption of mouse cytochrome p450 4f14 (Cyp4f14 gene) causes severe perturbations in vitamin E metabolism, J. Bio. Chem., 287, 26077, 10.1074/jbc.M112.373597 Brunt, 2010, Pathology of nonalcoholic fatty liver disease, Nat. Rev. Gastroenterol. Hepatol., 7, 195, 10.1038/nrgastro.2010.21 Buechler, 2011, Does hepatic steatosis affect drug metabolizing enzymes in the liver?, Curr. Drug Metab., 12, 24, 10.2174/138920011794520035 Clark, 2006, The epidemiology of nonalcoholic fatty liver disease in adults, J. Clin. Gastroenterol., 40, S5 Day, 1998, Steatohepatitis: a tale of two hits?, Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2 Fisher, 2009, Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats, Eur. J. Pharmacol., 613, 119, 10.1016/j.ejphar.2009.04.002 Gómez-Lechón, 2009, Cytochrome P450 and steatosis, Curr. Drug Metab., 10, 692, 10.2174/138920009789895543 Ishida, 2000, Insulin is a dominant suppressor of sterol 12a-hy- droxylase P450 (CYP8B) expression in rat liver: possible role of insulin in Orcadian rhythm of CYP8R, J. Biochem., 127, 57, 10.1093/oxfordjournals.jbchem.a022584 Kirpich, 2011, Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease, J. Nutr. Biochem., 22, 38, 10.1016/j.jnutbio.2009.11.009 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Kohjima, 2007, Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease, Int. J. Mol. Med., 20, 351 Li, 2011, Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis, Drug Metab. Dispos., 39, 571, 10.1124/dmd.110.036806 Li, 2013, Bile acid receptors in non-alcoholic fatty liver disease, Biochem. Pharmacol., 86, 1517, 10.1016/j.bcp.2013.08.015 Marchesini, 1999, Association of nonalcoholic fatty liver disease with insulin resistance, Am. J. Med., 107, 450, 10.1016/S0002-9343(99)00271-5 Ogawa, 2007, BetaKlotho is required for metabolic activity of fibroblast growth factor 21, Proc. Natl. Acad. Sci. U. S. A., 104, 7432, 10.1073/pnas.0701600104 Osabe, 2008, Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet, Drug Metab. Dispos., 36, 294, 10.1124/dmd.107.017731 Porter, 1991, Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms, J. Biol. Chem., 266, 13469, 10.1016/S0021-9258(18)92717-1 Rao, 2004, PPARalpha in the pathogenesis of fatty liver disease, Hepatology, 40, 783, 10.1002/hep.20453 Reddy, 2001, Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system, Annu. Rev. Nutr., 21, 193, 10.1146/annurev.nutr.21.1.193 Shi, 2013, Long Non-coding RNAs: a new frontier in the study of human diseases, Cancer Lett., 339, 159, 10.1016/j.canlet.2013.06.013 Spahis, 2015, Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: effect of n-3 PUFA supplementation, Prostaglandins Leukot. Essent. Fatty Acids, 99, 25, 10.1016/j.plefa.2015.04.010 Tan, 2013, Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury, Lab. Invest., 93, 1295, 10.1038/labinvest.2013.121 Tarantino, 2007, A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease, Hepatol. Res., 37, 410, 10.1111/j.1872-034X.2007.00072.x Tarantino, 2009, Drug-induced liver injury: is it somehow foreseeable?, World J. Gastroenterol., 15, 2817, 10.3748/wjg.15.2817 Timm, 2001, Structural basis of pheromone binding to mouse major urinary protein (MUP-I), Protein Sci., 10, 997, 10.1110/ps.52201 Tiniakos, 2010, Nonalcoholic fatty liver disease: pathology and pathogenesis, Annu. Rev. Pathol. Mech., 5, 145, 10.1146/annurev-pathol-121808-102132 Yan, 2001, Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study, PLoS One, 6, 24895, 10.1371/journal.pone.0024895 Yeh, 2007, Pathology of nonalcoholic fatty liver disease, Am. J. Clin. Pathol., 128, 837, 10.1309/RTPM1PY6YGBL2G2R Zhang, 2007, Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis, J. Pharmacol. Exp. Ther., 322, 770, 10.1124/jpet.107.124024 Zhang, 2013, Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma, Br. J. Cancer, 109, 14, 10.1038/bjc.2013.293